Review
Endocrinology & Metabolism
Johanna Melin, Maria Forslund, Simon Alesi, Terhi Piltonen, Daniela Romualdi, Poli Mara Spritzer, Chau Thien Tay, Alexia Pena, Selma Feldman Witchel, Aya Mousa, Helena Teede
Summary: This review evaluates the effectiveness of metformin and lifestyle modification compared with placebo in the management of PCOS and will inform the forthcoming, 2023 evidence-based PCOS guidelines. The results showed that metformin can reduce body mass index, insulin resistance, fasting glucose, waist-hip ratio, total cholesterol, low-density lipoprotein, and triglycerides in PCOS patients. Therefore, metformin should be considered as an efficacious adjunct to lifestyle interventions in adults with PCOS, especially for those with a higher BMI.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Review
Endocrinology & Metabolism
Jianguo Chen, Chaoran Huang, Tongtong Zhang, Wuqing Gong, Xiaofeng Deng, Hua Liu, Jinbo Liu, Yuanbiao Guo
Summary: Through a systematic review and meta-analysis, this study showed that statin treatment significantly reduced androgen levels and improved cutaneous manifestations in PCOS patients. Subgroup and sensitivity analysis confirmed the stability of the findings.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Qian Zhao, Jin He
Summary: This meta-analysis found that the use of metformin in pregnant women with polycystic ovarian syndrome (PCOS) can significantly reduce the risk of preterm delivery, early miscarriage, gestational diabetes, pre-eclampsia, the need for insulin treatment throughout pregnancy, and weight gain of pregnant women. No significant difference was observed in serious maternal adverse events.
GYNECOLOGICAL ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Wenjuan Shen, Yujia Pan, Bao Jin, Zongyu Zhang, Tianjiao You, Yangfan Qu, Mei Han, Xingxing Yuan, Yang Zhang
Summary: The study found that tea supplementation can significantly reduce blood glucose and insulin levels, as well as body weight in patients with PCOS, especially green tea. Tea supplements are a relatively safe treatment for PCOS patients.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Pharmacology & Pharmacy
Adriana F. S. Fontes, Fernando M. M. Reis, Ana Lucia Candido, Karina B. Gomes, Jessica A. G. Tosatti
Summary: The effects of metformin treatment on markers of hyperandrogenism in patients diagnosed with polycystic ovary syndrome (PCOS) were summarized in this study. The results of systematic review and meta-analysis showed that metformin treatment can significantly reduce total testosterone levels and regulate the free androgen index (FAI) values.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Obstetrics & Gynecology
Jie Meng, Yingjun Zhu
Summary: The meta-analysis showed that combined treatment with simvastatin plus metformin was more effective in treating polycystic ovary syndrome (PCOS) compared to metformin monotherapy, resulting in significantly reduced total testosterone, LH:FSH ratio, and LDL cholesterol levels.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
(2021)
Review
Obstetrics & Gynecology
Zheng-Rong Ye, Can-Qun Yan, Nianchun Liao, Si-Hua Wen
Summary: Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects women of childbearing age, causing reproductive dysfunction, hyperinsulinemia, and obesity. This meta-analysis compared the effectiveness and safety of exenatide, a glucagon-like peptide-1 receptor agonist, with metformin, an insulin sensitizer, in treating PCOS patients. The results showed that exenatide was more effective in increasing pregnancy rate, ovulation rate, decreasing body mass index, and improving insulin resistance compared to metformin. However, more high-quality studies are needed to provide stronger evidence for the use of exenatide in this patient population.
REPRODUCTIVE SCIENCES
(2023)
Article
Nutrition & Dietetics
Nahla Al-Bayyari, Hayder Al-Domi, Faheem Zayed, Ra'ed Hailat, Arieanna Eaton
Summary: The study demonstrated that weekly treatment with 50,000 IU of vitamin D-3 can improve 25(OH)D levels and decrease hirsutism scores and androgen levels in overweight women with PCOS. These results may lead to increased fertility and better reproductive health for these patients.
CLINICAL NUTRITION
(2021)
Review
Endocrinology & Metabolism
Anna Rong, Na Ta, Lihua E, Wenbin Meng
Summary: The add-on effect of Guizhi Fuling pill for treating reduced fertility potential in women with PCOS was evaluated through a systematic review and meta-analysis. Sixteen RCTs showed that the use of Guizhi Fuling pill in conjunction with Western medicine significantly improved ovulation and pregnancy rates, and decreased serum FSH, total testosterone, LH, and HOMA-IR levels. However, its impact on miscarriage rate and serum estradiol level remains inconclusive.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Endocrinology & Metabolism
Limei Wu, Ye Liu, Xi Huang, Kaiping Lin, Yang Liu, Zhizun Li, Tianqin Wei, Ling Song, Yuanyuan Hua, Xiaoli Wang
Summary: This study compared the effects of oral contraceptives (OCs) + metformin and OCs alone on metabolism in nonobese polycystic ovary syndrome (PCOS) patients. The results showed that in nonobese PCOS patients, OCs+metformin significantly improved fasting glucose and fasting insulin levels compared to OCs alone at the end of the study, but there were no significant differences in insulin resistance, high-density lipoprotein, low-density lipoprotein, total cholesterol or triglycerides between the two groups.
CLINICAL ENDOCRINOLOGY
(2023)
Review
Nutrition & Dietetics
Maryam Kazemi, Amir Hadi, Roger A. Pierson, Marla E. Lujan, Gordon A. Zello, Philip D. Chilibeck
Summary: The study found that a diet with low glycemic index (LGI) had significant effects on improving cardiometabolic and reproductive profiles in PCOS patients, including reducing insulin resistance, improving lipid metabolism, and decreasing abdominal fat.
ADVANCES IN NUTRITION
(2021)
Article
Endocrinology & Metabolism
Lili Liu, Wei Chen, Dan Wu, Fang Hu
Summary: This meta-analysis and systematic review suggests that time-restricted eating may be an effective approach to improving the metabolic state of nonobese individuals, particularly overweight individuals.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Huamin Zeng, Ying Zhang, Sikai Huang, Jinghua Wu, Wenrui Ren, Lingru Zhou, Leneng Huang, Yuyin Ye
Summary: Metformin combined with spironolactone therapy may be more effective in reducing BMI and serum androgen levels in PCOS patients. However, it does not have a significant effect on hirsutism score or gonadotropin hormone levels, and is not associated with an elevation in side-effects. When the treatment course is greater than 6 months, combination therapy can effectively reduce FBG and improve insulin resistance.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Endocrinology & Metabolism
Mohammed A. Abdalla, Najeeb Shah, Harshal Deshmukh, Amirhossein Sahebkar, Linda Ostlundh, Rami H. Al-Rifai, Stephen L. Atkin, Thozhukat Sathyapalan
Summary: This study reviewed the effect of different pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome. The results showed that metformin, sitagliptin, pioglitazone, rosiglitazone, orlistat, and acarbose had significant effects on body weight, body mass index (BMI), and waist circumference in women with PCOS.
CLINICAL ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Mohammed Altigani Abdalla, Najeeb Shah, Harshal Deshmukh, Amirhossein Sahebkar, Linda Ostlundh, Rami H. Al-Rifai, Stephen L. Atkin, Thozhukat Sathyapalan
Summary: Metformin has been shown to have a positive impact on the clinical and metabolic parameters of women with PCOS, including reducing body weight, BMI, total testosterone, androstenedione, 17-OHP, LDL-C, fasting blood glucose, and increasing the likelihood of pregnancy.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
(2022)